Furthermore, impairment of IFN-γ signaling by knocking down IFNGR1, led to resistance to HER2-TCB in cell lines from HER2-positive ovarian and lung cancers (Supplementary Fig. 4j, k). This evidence concerns the gene ERBB2 and lung cancer.